NASDAQ
34.26USD
+0.96 (+2.88%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
4B
P/E
—
EPS
—
Beta
0.66
52W range
22.959-43.15
Day range
33.21–34.31
Open
33.82
Prev close
33.30
Volume
1.3M
Avg volume
2.4M
Dividend
0.00
IPO
2015-04-28
https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-viking-therapeutics-inc-to-contact-law-firm-302831251.html · 7/21/2026-0.80
https://www.fool.com/investing/2026/07/18/watch-out-eli-lilly-and-novo-nordisk-viking-just/ · 7/18/2026+0.40
https://www.globenewswire.com/news-release/2026/07/17/3328891/0/en/Kuehn-Law-Encourages-Investors-of-Quantum-Computing-Inc-to-Contact-Law-Firm.html · 7/17/2026-0.80
https://seekingalpha.com/article/4921194-viking-therapeutics-still-cheap-but-watch-double-top · 7/10/2026+1.00
https://247wallst.com/investing/2026/07/09/jim-cramer-says-biotech-is-the-hottest-group-in-the-market-right-now/ · 7/9/2026+0.20
https://www.fool.com/investing/2026/07/04/is-viking-therapeutics-stock-going-to-50-heres-wha/ · 7/4/2026+0.60
https://seekingalpha.com/article/4918920-viking-therapeutics-updating-pipeline-potential-as-oral-glp1s-accelerate · 6/30/2026+0.10
https://www.fool.com/investing/2026/06/23/is-viking-therapeutics-stock-a-no-brainer-buy-belo/ · 6/23/2026+0.60
https://www.fool.com/investing/2026/06/22/why-this-mid-cap-biotech-could-be-the-dark-horse-t/ · 6/23/2026+0.80
https://www.zacks.com/stock/news/2939022/viking-therapeutics-inc-vktx-gains-as-market-dips-what-you-should-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6v1-2939022 · 6/17/2026+0.20
https://www.fool.com/investing/2026/06/12/is-viking-therapeutics-going-to-100/ · 6/12/2026+0.80
https://www.zacks.com/stock/news/2935502/viking-therapeutics-inc-vktx-falls-more-steeply-than-broader-market-what-investors-need-to-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6v1-2935502 · 6/10/2026-0.60
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
